Multiple Dose Study of Safety and Pharmacokinetics of MEDI0618 in Healthy Volunteers
A Randomised, Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of MEDI0618 in Healthy Male and Female Volunteers
This is a single centre, randomised, double-blind, placebo-controlled, multiple ascending dose study of MEDI0618 in healthy male and female volunteers.
Subjects will receive MEDI0618 or placebo administered by intravenous infusion or subcutaneous injection.
Safety, tolerability and pharmacokinetics of multiple ascending doses of MEDI0618 will be assessed.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: AstraZeneca Clinical Study Information Center
- Phone Number: 1-877-240-9479
- Email: information.center@astrazeneca.com
Study Locations
-
-
-
Berlin, Germany, 10117
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy men and women of non-child bearing potential
- Aged 18 to 50 years, inclusive
- Weigh more than 50 kg
- Body Mass Index between 18 to 30 kg/m2
- Healthy, in the opinion of the Principal Investigator
- Able to understand and comply with the protocol requirements
Exclusion Criteria:
- Participation in another clinical study with a study drug within 5 half-lives of that study drug or within 3 months prior to screening, whichever is longer
- Donation of blood or plasma within 2 months prior to screening and until after the final follow-up visit
- Poor venous access
- History of severe allergy/hypersensitivity reactions or history of hypersensitivity to immunisations, immunoglobulins or biologics
- Prescence of any clinically significant illness, such as cardiovascular, neurological, pulmonary, hepatic, renal, metabolic, gastro-intestinal, urologic, immunologic or endocrine disease or disorder
- History of cancer within 5 years of screening
- History of drug abuse
- Use of prescriptions or non-prescription medicines within 7 days or 5 half-lives, whichever is longer, prior to administration of study treatments
- Any clinical abnormality on complete physical examination, vitals signs, ECG or clinical laboratory test results at screening or between screening and randomisation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: MEDI0618
A human immunoglobulin antibody to the Protease Activated Receptor 2 (PAR2)
|
Four doses of 100 mg IV, 200 mg IV or 200 mg SC MEDI0618 administered once every two weeks.
Other Names:
|
|
Placebo Comparator: Placebo
Histidine/histidine HCl, sucrose and polysorbate
|
Four doses of IV placebo or SC placebo administered once every two weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of adverse events
Time Frame: From Screening, Day 1 to Day 113
|
To characterise the safety and tolerability of MEDI0618 administered IV or SC
|
From Screening, Day 1 to Day 113
|
|
Incidence of abnormal vital signs
Time Frame: From Screening, Day 1 to Day 113
|
To characterise the safety and tolerability of MEDI0618 administered IV or SC
|
From Screening, Day 1 to Day 113
|
|
Incidence of abnormal laboratory parameters
Time Frame: Day -1, Day 15, Day 29, Day 43, Day 57, Day 71, Day 99, Day 113
|
To characterise the safety and tolerability of MEDI0618 administered IV or SC
|
Day -1, Day 15, Day 29, Day 43, Day 57, Day 71, Day 99, Day 113
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to maximum observed plasma concentration (Tmax) of MEDI0618
Time Frame: Day 1 to Day 113
|
To characterise the pharmacokinetic (PK) profile of MEDI0618 administered IV or SC
|
Day 1 to Day 113
|
|
Maximum observed plasma concentration (Cmax) of MEDI0618
Time Frame: Day 1 to Day 113
|
To characterise the pharmacokinetic (PK) profile of MEDI0618 administered IV or SC
|
Day 1 to Day 113
|
|
Area under plasma concentration-time curve over dosing interval (AUC[tau]) of MEDI0618
Time Frame: Day 1 to Day 113
|
To characterise the pharmacokinetic (PK) profile of MEDI0618 administered IV or SC
|
Day 1 to Day 113
|
|
Pre-dose trough concentration (Ctrough) of MEDI0618
Time Frame: Day 1 to Day 113
|
To characterise the pharmacokinetic (PK) profile of MEDI0618 administered IV or SC
|
Day 1 to Day 113
|
|
The volume of plasma cleared of drug per unit time (CL) of MEDI0618
Time Frame: Day 1 to Day 113
|
To characterise the pharmacokinetic (PK) profile of MEDI0618 administered IV or SC
|
Day 1 to Day 113
|
|
Anti-drug antibodies (ADA)
Time Frame: Day 1, Day 8, Day 29, Day 43, Day 57, Day 71, Day 99, Day 113
|
To characterise the immunogenicity of MEDI0618 administered IV or SC
|
Day 1, Day 8, Day 29, Day 43, Day 57, Day 71, Day 99, Day 113
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Stanislav Ignatenko, Charite Research Organisation, Berlin Germany
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- D7060C00002
- 2022-002889-32 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.